-
1
-
-
33645052218
-
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention)
-
Smith SC, Jr. Feldman TE, Hirshfeld JW, Jr. et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286.
-
(2006)
Circulation
, vol.113
-
-
Smith Jr., S.C.1
Feldman, T.E.2
Hirshfeld Jr, J.W.3
-
2
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
-
(2007)
N Engl J Med
, vol.357
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
-
3
-
-
70149101223
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
-
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
-
(2009)
N Engl J Med
, vol.361
, pp. 1045-1057
-
-
Wallentin, L.1
Becker, R.C.2
Budaj, A.3
-
4
-
-
0034762075
-
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement
-
Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
-
(2001)
Heart
, vol.85
, pp. 92-93
-
-
Muller, I.1
Seyfarth, M.2
Rudiger, S.3
-
5
-
-
0038649988
-
Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity
-
Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
-
(2003)
Circulation
, vol.107
, pp. 2908-2913
-
-
Gurbel, P.A.1
Bliden, K.P.2
Hiatt, B.L.3
-
6
-
-
11844256436
-
Variability in platelet responsiveness to clopidogrel among 544 individuals
-
Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
-
(2005)
J Am Coll Cardiol
, vol.45
, pp. 246-251
-
-
Serebruany, V.L.1
Steinhubl, S.R.2
Berger, P.B.3
-
7
-
-
77953911457
-
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
-
Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 919-933
-
-
Bonello, L.1
Tantry, U.S.2
Marcucci, R.3
-
8
-
-
60949083948
-
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis
-
Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
-
(2009)
J Am Coll Cardiol
, vol.53
, pp. 849-856
-
-
Sibbing, D.1
Braun, S.2
Morath, T.3
-
9
-
-
77955603691
-
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: Initial evidence of a therapeutic window
-
Sibbing D, Steinhubl SR, Schulz S, et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56: 317-318.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 317-318
-
-
Sibbing, D.1
Steinhubl, S.R.2
Schulz, S.3
-
10
-
-
38949179203
-
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point
-
Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-697.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 690-697
-
-
Ndrepepa, G.1
Berger, P.B.2
Mehilli, J.3
-
11
-
-
70249101426
-
Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: A report from the platelet physiology subcommittee of the SSC of the ISTH
-
Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7: 1029.
-
(2009)
J Thromb Haemost
, vol.7
, pp. 1029
-
-
Cattaneo, M.1
Hayward, C.P.2
Moffat, K.A.3
-
13
-
-
33947328091
-
Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance
-
Siller-Matula J, Schrör K, Wojta J, et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
-
(2007)
Thromb Haemost
, vol.97
, pp. 385-393
-
-
Siller-Matula, J.1
Schrör, K.2
Wojta, J.3
-
14
-
-
70549107994
-
Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of "resistance
-
Serebruany V, Cherala G, Williams C, et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". Am Heart J 2009; 158: 925-932.
-
(2009)
Am Heart J
, vol.158
, pp. 925-932
-
-
Serebruany, V.1
Cherala, G.2
Williams, C.3
-
15
-
-
34447274446
-
Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention
-
Sibbing D, von Beckerath O, Schomig A, et al. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007; 100: 203-205.
-
(2007)
Am J Cardiol
, vol.100
, pp. 203-205
-
-
Sibbing, D.1
von Beckerath, O.2
Schomig, A.3
-
16
-
-
11144355993
-
Platelet aggregation according to body mass index in patients undergoing coronary stenting: Should clopidogrel loading-dose be weight adjusted?
-
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004; 16: 169-174.
-
(2004)
J Invasive Cardiol
, vol.16
, pp. 169-174
-
-
Angiolillo, D.J.1
Fernandez-Ortiz, A.2
Bernardo, E.3
-
17
-
-
23644433510
-
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
-
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435.
-
(2005)
Diabetes
, vol.54
, pp. 2430-2435
-
-
Angiolillo, D.J.1
Fernandez-Ortiz, A.2
Bernardo, E.3
-
18
-
-
37549006004
-
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score
-
Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
-
(2008)
J Thromb Haemost
, vol.6
, pp. 54-61
-
-
Geisler, T.1
Grass, D.2
Bigalke, B.3
-
19
-
-
44349185490
-
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease
-
Geisler T, Kapp M, Gohring-Frischholz K, et al. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008; 94: 743-747.
-
(2008)
Heart
, vol.94
, pp. 743-747
-
-
Geisler, T.1
Kapp, M.2
Gohring-Frischholz, K.3
-
20
-
-
65449170730
-
Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention
-
Price MJ, Nayak KR, Barker CM, et al. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 103: 1339-1343.
-
(2009)
Am J Cardiol
, vol.103
, pp. 1339-1343
-
-
Price, M.J.1
Nayak, K.R.2
Barker, C.M.3
-
21
-
-
76049120468
-
A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction
-
Osmancik P, Jirmar R, Hulikova K, et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 2010; 75: 158-166.
-
(2010)
Catheter Cardiovasc Interv
, vol.75
, pp. 158-166
-
-
Osmancik, P.1
Jirmar, R.2
Hulikova, K.3
-
22
-
-
78649732206
-
Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment
-
Bernlochner I, Steinhubl S, Braun S, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 2010; 104: 1193-1200.
-
(2010)
Thromb Haemost
, vol.104
, pp. 1193-1200
-
-
Bernlochner, I.1
Steinhubl, S.2
Braun, S.3
-
23
-
-
48449101872
-
The association of cigarette smoking with enhanced platelet inhibition by clopidogrel
-
Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008; 52: 531-533.
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 531-533
-
-
Bliden, K.P.1
Dichiara, J.2
Lawal, L.3
-
24
-
-
77958505560
-
Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
-
author reply
-
Gurbel PA, Tantry US, Shuldiner AR. Letter by Gurbel et al. regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement". Circulation 2010; 122: e478; author reply e479.
-
(2010)
Circulation
, vol.122
-
-
Gurbel, P.A.1
Tantry, U.S.2
Shuldiner, A.R.3
-
25
-
-
67849119987
-
Platelet reactivity and stent thrombosis: Still some issues to solve
-
author reply
-
Perez de Prado A, Cuellas C, Diego A, et al. Platelet reactivity and stent thrombosis: still some issues to solve. J Am Coll Cardiol 2009; 54: 666-667; author reply 667-668.
-
(2009)
J Am Coll Cardiol
, vol.54
, pp. 666-667
-
-
de Perez, P.A.1
Cuellas, C.2
Diego, A.3
-
26
-
-
57149104093
-
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
-
Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148 e1-5.
-
(2009)
Am Heart J
, vol.157
, Issue.148
-
-
Siller-Matula, J.M.1
Spiel, A.O.2
Lang, I.M.3
-
27
-
-
64849087438
-
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
-
Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
-
(2009)
Thromb Haemost
, vol.101
, pp. 714-719
-
-
Sibbing, D.1
Morath, T.2
Stegherr, J.3
-
28
-
-
38349065084
-
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
-
Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 256-260
-
-
Gilard, M.1
Arnaud, B.2
Cornily, J.C.3
-
29
-
-
61549124132
-
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
-
Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J Am Med Assoc 2009; 301: 937-944.
-
(2009)
J Am Med Assoc
, vol.301
, pp. 937-944
-
-
Ho, P.M.1
Maddox, T.M.2
Wang, L.3
-
30
-
-
62649164844
-
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
-
Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718.
-
(2009)
CMAJ
, vol.180
, pp. 713-718
-
-
Juurlink, D.N.1
Gomes, T.2
Ko, D.T.3
-
31
-
-
70249144272
-
Risk of combining PPIs with thienopyridines: Fact or fiction?
-
Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction? Lancet 2009; 374: 952-954.
-
(2009)
Lancet
, vol.374
, pp. 952-954
-
-
Sibbing, D.1
Kastrati, A.2
-
32
-
-
78149487926
-
Clopidogrel with or without omeprazole in coronary artery disease
-
Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-1917.
-
(2010)
N Engl J Med
, vol.363
, pp. 1909-1917
-
-
Bhatt, D.L.1
Cryer, B.L.2
Contant, C.F.3
-
33
-
-
70249139788
-
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials
-
O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
-
(2009)
Lancet
, vol.374
, pp. 989-997
-
-
O'Donoghue, M.L.1
Braunwald, E.2
Antman, E.M.3
-
34
-
-
64849105131
-
Clopidogrel and proton pump inhibitors: Gastric protection at expense of vascular benefit?
-
Serebruany V, Goto S. Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit? Thromb Haemost 2009; 101: 607-609.
-
(2009)
Thromb Haemost
, vol.101
, pp. 607-609
-
-
Serebruany, V.1
Goto, S.2
-
35
-
-
65349111293
-
The drug-drug interaction between proton pump inhibitors and clopidogrel
-
Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 699-700.
-
(2009)
CMAJ
, vol.180
, pp. 699-700
-
-
Lau, W.C.1
Gurbel, P.A.2
-
36
-
-
0037422534
-
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction
-
Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37.
-
(2003)
Circulation
, vol.107
, pp. 32-37
-
-
Lau, W.C.1
Waskell, L.A.2
Watkins, P.B.3
-
37
-
-
77952048536
-
The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response
-
Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103: 920-925.
-
(2010)
Thromb Haemost
, vol.103
, pp. 920-925
-
-
Harmsze, A.M.1
Robijns, K.2
van Werkum, J.W.3
-
38
-
-
54349121974
-
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel
-
Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 1557-1563
-
-
Siller-Matula, J.M.1
Lang, I.2
Christ, G.3
-
39
-
-
77952400164
-
Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel
-
Sibbing D, von Beckerath N, Morath T, et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 2010; 31: 1205-1211.
-
(2010)
Eur Heart J
, vol.31
, pp. 1205-1211
-
-
Sibbing, D.1
von Beckerath, N.2
Morath, T.3
-
40
-
-
79952444959
-
Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting
-
Sarafoff N, Neumann L, Morath T, et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011; 161: 605-610.
-
(2011)
Am Heart J
, vol.161
, pp. 605-610
-
-
Sarafoff, N.1
Neumann, L.2
Morath, T.3
-
41
-
-
0042780283
-
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial
-
Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-924.
-
(2003)
Circulation
, vol.108
, pp. 921-924
-
-
Saw, J.1
Steinhubl, S.R.2
Berger, P.B.3
-
42
-
-
7544244139
-
Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting
-
Nov
-
Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004 Nov;25(21):1898-902.
-
(2004)
Eur Heart J
, vol.25
, Issue.21
, pp. 1898-902
-
-
Gorchakova, O.1
von Beckerath, N.2
Gawaz, M.3
-
43
-
-
53649098316
-
Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation
-
Sarafoff N, Ndrepepa G, Mehilli J, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 2008; 264: 472-480.
-
(2008)
J Intern Med
, vol.264
, pp. 472-480
-
-
Sarafoff, N.1
Ndrepepa, G.2
Mehilli, J.3
-
44
-
-
58749094444
-
Cytochrome p-450 polymorphisms and response to clopidogrel
-
Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
-
(2009)
N Engl J Med
, vol.360
, pp. 354-362
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
45
-
-
69249219296
-
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
-
Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009; 302: 849-857.
-
(2009)
J Am Med Assoc
, vol.302
, pp. 849-857
-
-
Shuldiner, A.R.1
O'Connell, J.R.2
Bliden, K.P.3
-
46
-
-
77955416969
-
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
-
Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010; 8: 1685-1693.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 1685-1693
-
-
Sibbing, D.1
Gebhard, D.2
Koch, W.3
-
47
-
-
76349098199
-
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
-
Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-518.
-
(2010)
Circulation
, vol.121
, pp. 512-518
-
-
Sibbing, D.1
Koch, W.2
Gebhard, D.3
-
48
-
-
65249145201
-
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
-
Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-922.
-
(2009)
Eur Heart J
, vol.30
, pp. 916-922
-
-
Sibbing, D.1
Stegherr, J.2
Latz, W.3
-
49
-
-
58749090547
-
Genetic determinants of response to clopidogrel and cardiovascular events
-
Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
-
(2009)
N Engl J Med
, vol.360
, pp. 363-375
-
-
Simon, T.1
Verstuyft, C.2
Mary-Krause, M.3
-
50
-
-
73149119363
-
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
-
Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-99.
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 92-99
-
-
Kazui, M.1
Nishiya, Y.2
Ishizuka, T.3
-
51
-
-
1642453779
-
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
-
Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-171.
-
(2004)
Circulation
, vol.109
, pp. 166-171
-
-
Lau, W.C.1
Gurbel, P.A.2
Watkins, P.B.3
-
52
-
-
43049179414
-
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
-
Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 1925-1934
-
-
Trenk, D.1
Hochholzer, W.2
Fromm, M.F.3
-
53
-
-
78049326068
-
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis
-
Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. J Am Med Assoc 2010; 304: 1821-1830.
-
(2010)
J Am Med Assoc
, vol.304
, pp. 1821-1830
-
-
Mega, J.L.1
Simon, T.2
Collet, J.P.3
-
54
-
-
77953896604
-
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis
-
Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134-143.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 134-143
-
-
Hulot, J.S.1
Collet, J.P.2
Silvain, J.3
-
55
-
-
77955425743
-
ACCF/AHA Clopidogrel clinical alert: Approaches to the FDA "boxed warning": A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
-
Holmes DR, Jr., Dehmer GJ, Kaul S, et al. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010; 122: 537-557.
-
(2010)
Circulation
, vol.122
, pp. 537-557
-
-
Holmes Jr., D.R.1
Dehmer, G.J.2
Kaul, S.3
-
56
-
-
77955416969
-
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
-
Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010; 8: 1685-1693.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 1685-1693
-
-
Sibbing, D.1
Gebhard, D.2
Koch, W.3
-
57
-
-
78049433100
-
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
-
Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363: 1704-1714.
-
(2010)
N Engl J Med
, vol.363
, pp. 1704-1714
-
-
Pare, G.1
Mehta, S.R.2
Yusuf, S.3
-
58
-
-
30344457586
-
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
-
Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-113.
-
(2006)
Clin Pharmacol Ther
, vol.79
, pp. 103-113
-
-
Sim, S.C.1
Risinger, C.2
Dahl, M.L.3
-
59
-
-
77958100874
-
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial
-
Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
-
(2010)
Lancet
, vol.376
, pp. 1320-1328
-
-
Wallentin, L.1
James, S.2
Storey, R.F.3
-
61
-
-
77958105401
-
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis
-
Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-1319.
-
(2010)
Lancet
, vol.376
, pp. 1312-1319
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
62
-
-
78651239845
-
Paraoxonase-1 is a major determinant of clopidogrel efficacy
-
Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
-
(2011)
Nat Med
, vol.17
, pp. 110-116
-
-
Bouman, H.J.1
Schomig, E.2
van Werkum, J.W.3
-
63
-
-
0030590746
-
Blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
-
CAPRIE Steering Committee
-
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
-
(1996)
Lancet
, vol.348
, pp. 1329-1339
-
-
Randomised, A.1
-
64
-
-
0035967496
-
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study
-
Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-2578.
-
(2001)
Circulation
, vol.103
, pp. 2572-2578
-
-
Steinhubl, S.R.1
Talley, J.D.2
Braden, G.A.3
-
65
-
-
0038354521
-
Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation
-
Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
-
(2003)
Catheter Cardiovasc Interv
, vol.59
, pp. 295-302
-
-
Barragan, P.1
Bouvier, J.L.2
Roquebert, P.O.3
-
66
-
-
8344221349
-
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
-
Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
-
(2004)
Circulation
, vol.109
, pp. 3171-3175
-
-
Matetzky, S.1
Shenkman, B.2
Guetta, V.3
-
67
-
-
27644536235
-
Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study
-
Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
-
(2005)
J Am Coll Cardiol
, vol.46
, pp. 1820-1826
-
-
Gurbel, P.A.1
Bliden, K.P.2
Guyer, K.3
-
68
-
-
33750479499
-
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
-
Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
-
(2006)
J Am Coll Cardiol
, vol.48
, pp. 1742-1750
-
-
Hochholzer, W.1
Trenk, D.2
Bestehorn, H.P.3
-
69
-
-
34250020766
-
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
-
Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 2312-2317
-
-
Buonamici, P.1
Marcucci, R.2
Migliorini, A.3
-
70
-
-
44949173754
-
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
-
Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
-
(2008)
Eur Heart J
, vol.29
, pp. 992-1000
-
-
Price, M.J.1
Endemann, S.2
Gollapudi, R.R.3
-
71
-
-
77249113768
-
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
-
Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
-
(2010)
J Am Med Assoc
, vol.303
, pp. 754-762
-
-
Breet, N.J.1
van Werkum, J.W.2
Bouman, H.J.3
-
72
-
-
74749094606
-
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay
-
Siller-Matula JM, Christ G, Lang IM, et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010; 8: 351-359.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 351-359
-
-
Siller-Matula, J.M.1
Christ, G.2
Lang, I.M.3
-
73
-
-
77953159705
-
Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function
-
Judge HM, Buckland RJ, Sugidachi A, et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103: 1210-1217.
-
(2010)
Thromb Haemost
, vol.103
, pp. 1210-1217
-
-
Judge, H.M.1
Buckland, R.J.2
Sugidachi, A.3
-
74
-
-
34447636769
-
Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
-
Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 1630-1636
-
-
Bonello, L.1
Paganelli, F.2
Arpin-Bornet, M.3
-
75
-
-
56549090507
-
Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target
-
Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008; 19: 595-604.
-
(2008)
Platelets
, vol.19
, pp. 595-604
-
-
Gurbel, P.A.1
Antonino, M.J.2
Bliden, K.P.3
-
76
-
-
59849120163
-
Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up
-
Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-242.
-
(2009)
Circulation
, vol.119
, pp. 237-242
-
-
Marcucci, R.1
Gori, A.M.2
Paniccia, R.3
-
77
-
-
36949000480
-
The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis
-
Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
-
(2007)
Thromb Haemost
, vol.98
, pp. 1329-1334
-
-
Blindt, R.1
Stellbrink, K.2
de Taeye, A.3
-
78
-
-
79956319559
-
Standard versus high-dose clopidogrel according to platelet function testing after PCI: Results of the GRAVITAS trial
-
Price MJ. Standard versus high-dose clopidogrel according to platelet function testing after PCI: Results of the GRAVITAS trial. Circulation 2010; 122: 2215-2226.
-
(2010)
Circulation
, vol.122
, pp. 2215-2226
-
-
Price, M.J.1
-
79
-
-
34548542073
-
Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis
-
Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-948.
-
(2007)
Lancet
, vol.370
, pp. 937-948
-
-
Stettler, C.1
Wandel, S.2
Allemann, S.3
-
80
-
-
77953914576
-
The Case for Routine Genotyping in Dual-Antiplatelet Therapy
-
Damani SB, Topol EJ. The Case for Routine Genotyping in Dual-Antiplatelet Therapy. J Am Coll Cardiol 2010; 56: 109-111.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 109-111
-
-
Damani, S.B.1
Topol, E.J.2
-
81
-
-
2142818494
-
The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition
-
Gurbel PA, Bliden KP, Hiatt BL. The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition. J Thromb Haemost 2003; 1: 1319-1321.
-
(2003)
J Thromb Haemost
, vol.1
, pp. 1319-1321
-
-
Gurbel, P.A.1
Bliden, K.P.2
Hiatt, B.L.3
-
82
-
-
0037406216
-
Durability of platelet inhibition by clopidogrel
-
Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003; 91: 1123-1125.
-
(2003)
Am J Cardiol
, vol.91
, pp. 1123-1125
-
-
Gurbel, P.A.1
Bliden, K.P.2
-
83
-
-
78651082582
-
Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients
-
Jaitner J, Stegherr J, Morath T, et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011; 105: 107-112.
-
(2011)
Thromb Haemost
, vol.105
, pp. 107-112
-
-
Jaitner, J.1
Stegherr, J.2
Morath, T.3
-
84
-
-
74249104162
-
Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting
-
Sibbing D, Morath T, Braun S, et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
-
(2010)
Thromb Haemost
, vol.103
, pp. 151-159
-
-
Sibbing, D.1
Morath, T.2
Braun, S.3
-
85
-
-
73949100670
-
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions
-
Geisler T, Zurn C, Simonenko R, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59-66.
-
(2010)
Eur Heart J
, vol.31
, pp. 59-66
-
-
Geisler, T.1
Zurn, C.2
Simonenko, R.3
-
86
-
-
0027531953
-
A method to determine the optimal intensity of oral anticoagulant therapy
-
Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
-
(1993)
Thromb Haemost
, vol.69
, pp. 236-239
-
-
Rosendaal, F.R.1
Cannegieter, S.C.2
van der Meer, F.J.3
-
87
-
-
74749097435
-
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement
-
Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250-256.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 250-256
-
-
Sibbing, D.1
Schulz, S.2
Braun, S.3
-
88
-
-
41249093357
-
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study
-
Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 1404-1411
-
-
Bonello, L.1
Camoin-Jau, L.2
Arques, S.3
-
89
-
-
58149476444
-
Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
-
Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
-
(2009)
Am J Cardiol
, vol.103
, pp. 5-10
-
-
Bonello, L.1
Camoin-Jau, L.2
Armero, S.3
-
90
-
-
45549084213
-
Pharmacokinetics of clopidogrel in patients with stent thrombosis
-
Sibbing D, Taubert D, Schomig A, et al. Pharmacokinetics of clopidogrel in patients with stent thrombosis. J Thromb Haemost 2008; 6: 1230-1232.
-
(2008)
J Thromb Haemost
, vol.6
, pp. 1230-1232
-
-
Sibbing, D.1
Taubert, D.2
Schomig, A.3
-
91
-
-
70349785594
-
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
-
Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 2009; 5: 325-329.
-
(2009)
EuroIntervention
, vol.5
, pp. 325-329
-
-
Cuisset, T.1
Cayla, G.2
Frere, C.3
-
92
-
-
33645982865
-
High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
-
Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-549.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 542-549
-
-
Cuisset, T.1
Frere, C.2
Quilici, J.3
-
93
-
-
77951615507
-
Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation
-
Eshtehardi P, Windecker S, Cook S, et al. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am Heart J 2010; 159: 891-898 e1.
-
(2010)
Am Heart J
, vol.159
-
-
Eshtehardi, P.1
Windecker, S.2
Cook, S.3
-
94
-
-
35048856897
-
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non- ST elevation acute coronary syndrome
-
Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non- ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
-
(2007)
Thromb Haemost
, vol.98
, pp. 838-843
-
-
Frere, C.1
Cuisset, T.2
Quilici, J.3
-
95
-
-
33749503499
-
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
-
Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
-
(2006)
Eur Heart J
, vol.27
, pp. 2420-2425
-
-
Geisler, T.1
Langer, H.2
Wydymus, M.3
-
96
-
-
49349114160
-
Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents
-
Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739.
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 734-739
-
-
Gori, A.M.1
Marcucci, R.2
Migliorini, A.3
-
97
-
-
27644465874
-
Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study
-
Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
-
(2005)
J Am Coll Cardiol
, vol.46
, pp. 1827-1832
-
-
Gurbel, P.A.1
Bliden, K.P.2
Samara, W.3
-
98
-
-
73449106079
-
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease
-
Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 2009; 120: 2214-2221.
-
(2009)
Circulation
, vol.120
, pp. 2214-2221
-
-
Migliorini, A.1
Valenti, R.2
Marcucci, R.3
-
99
-
-
51649108832
-
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study
-
Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008; 52: 1128-1133.
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 1128-1133
-
-
Patti, G.1
Nusca, A.2
Mangiacapra, F.3
|